Quality-of-life assessment during eculizumab treatment
Domain* . | Mean baseline score† . | 64-wk change from baseline score‡ . | P§ . |
|---|---|---|---|
| Global health status | 56.1 | 13.8 | .009 |
| Physical functioning | 70.9 | 14.3 | <.001 |
| Emotional functioning | 70.5 | 12.5 | <.001 |
| Role functioning | 66.7 | 14.5 | .003 |
| Cognitive functioning | 77.3 | 10.3 | .001 |
| Fatigue | 47.5 | −17.8 | <.001 |
| Dyspnea | 39.4 | −16.6 | <.001 |
| Insomnia | 30.3 | −8.2 | .031 |
| Pain | 21.2 | −8.2 | .023 |
| Constipation | 3.0 | 4.1 | <.001 |
Domain* . | Mean baseline score† . | 64-wk change from baseline score‡ . | P§ . |
|---|---|---|---|
| Global health status | 56.1 | 13.8 | .009 |
| Physical functioning | 70.9 | 14.3 | <.001 |
| Emotional functioning | 70.5 | 12.5 | <.001 |
| Role functioning | 66.7 | 14.5 | .003 |
| Cognitive functioning | 77.3 | 10.3 | .001 |
| Fatigue | 47.5 | −17.8 | <.001 |
| Dyspnea | 39.4 | −16.6 | <.001 |
| Insomnia | 30.3 | −8.2 | .031 |
| Pain | 21.2 | −8.2 | .023 |
| Constipation | 3.0 | 4.1 | <.001 |
Quality of life was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 instrument.
Mean values of linearly transformed scores.
Values represent least-square means. Positive change indicates improvement on Global Health Status and Functional scales, and negative change indicates improvement on Symptom scales.
From a mixed analysis-of-covariance model with visit as a fixed effect, patient as a random effect, and baseline as a covariate.